Department of Otorhinolaryngology - Head & Neck Surgery, Rush University Medical Center, Chicago, IL, United States of America.
Department of Otolaryngology - Head and Neck Surgery, University of Minnesota, Minneapolis, MN, United States of America.
Am J Otolaryngol. 2021 Nov-Dec;42(6):103076. doi: 10.1016/j.amjoto.2021.103076. Epub 2021 Apr 24.
No study to date has analyzed the progression of sinonasal symptoms over time in COVID-19 patients. The purpose of this study is to analyze the progression of sinonasal symptoms and risk factors for olfactory dysfunction in the mild severity COVID-19 patient.
An internet survey was used to assess sinonasal symptoms in patients with COVID-19. Changes in rhinologic domain and symptom-specific Sinonasal Outcome Test (SNOT-22) scores were compared at five time points: two weeks before diagnosis, at diagnosis, two weeks after diagnosis, four weeks after diagnosis, and six months after diagnosis.
521 responses were collected. Rhinologic domain SNOT-22 scores increased significantly (p < 0.001) to 8.94 at the time of diagnosis, remained elevated two weeks post-diagnosis (5.14, p = 0.004), and decreased significantly four weeks post-diagnosis (3.14, p = 0.004). Smell-specific SNOT-22 scores peaked at the time of diagnosis (2.05, p < 0.001), remained elevated two weeks after diagnosis (1.19, p < 0.001), and returned to baseline four weeks post-diagnosis (0.64, p > 0.999). Taste-specific SNOT-22 scores also peaked at diagnosis (2.06, p < 0.001), remained elevated two weeks after diagnosis (1.19, p < 0.001), and returned to baseline four weeks after diagnosis (0.71, p > 0.999). There were no significant differences in sense of smell or taste between 1-month and 6-month timepoints.
Sinonasal symptoms, particularly loss of smell and taste, may be important presenting symptoms in the mild severity COVID-19 patient. Our findings support incorporating these symptoms into screening protocols.
目前尚无研究分析 COVID-19 患者的鼻-鼻窦症状随时间的进展情况。本研究旨在分析轻度 COVID-19 患者的鼻-鼻窦症状进展和嗅觉功能障碍的危险因素。
采用互联网调查评估 COVID-19 患者的鼻-鼻窦症状。在五个时间点比较鼻科学域和症状特异性鼻-鼻窦炎结局测试(SNOT-22)评分的变化:诊断前两周、诊断时、诊断后两周、诊断后四周和诊断后六个月。
共收集 521 份回复。鼻科学域 SNOT-22 评分在诊断时显著升高(p<0.001),达到 8.94,诊断后两周仍升高(5.14,p=0.004),诊断后四周显著下降(3.14,p=0.004)。嗅觉特异性 SNOT-22 评分在诊断时达到峰值(2.05,p<0.001),诊断后两周仍升高(1.19,p<0.001),四周后恢复基线(0.64,p>0.999)。味觉特异性 SNOT-22 评分也在诊断时达到峰值(2.06,p<0.001),诊断后两周仍升高(1.19,p<0.001),四周后恢复基线(0.71,p>0.999)。1 个月和 6 个月时嗅觉和味觉无显著差异。
鼻-鼻窦症状,特别是嗅觉和味觉丧失,可能是轻度 COVID-19 患者的重要首发症状。我们的研究结果支持将这些症状纳入筛查方案。
4 级